CSPC Pharmaceutical Group Limited
CSPCY | OTC
$4.07
+$0.13 (+3.30%)
Nov 2, 2026, 10:20 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q4 2025 Dec 31, 2025 | Q2 2025 Jun 30, 2025 | Q4 2024 Dec 31, 2024 | Q2 2024 Jun 30, 2024 | Q4 2023 Dec 31, 2023 | Q2 2023 Jun 30, 2023 | Q4 2022 Dec 31, 2022 | Q2 2022 Jun 30, 2022 | Q4 2021 Dec 31, 2021 | Q2 2021 Jun 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Cash & Equivalents | 10B | 6.09B | 7.57B | 6.78B | 8.37B | 11.98B | 10.47B | 10.3B | 9.07B | 9.27B | 8.09B |
Short-Term Investments | 8.48B | 2.78B | 2.13B | 1.47B | 2.44B | 1.07B | 1.63B | 3.57B | 4.35B | 1.44B | 2.98B |
Long-Term Investments | 7.56B | 7.18B | 6.66B | 4.8B | 6.44B | 4.64B | 3.03B | 3.73B | 3.36B | 3.6B | 3.53B |
Other Long-Term Assets | 566.41M | 556.73M | 4.4M | 1.53B | 50.67M | 50.65M | 2.25B | -34.85M | 768.26M | 419.13M | 197.57M |
Receivables | 8.47B | 9.55B | 9.44B | 9.94B | 11.91B | 10.13B | 8.76B | 7.53B | 6.23B | 6.52B | 5.8B |
Inventory | 2.96B | 3.09B | 2.87B | 3.13B | 3.46B | 3.45B | 2.75B | 2.55B | 2.62B | 2.48B | 1.83B |
Other Current Assets | 684.87M | 534.26M | 413.66M | 362.35M | 83.9M | -104.13M | 10.26B | -693.22M | 563.65M | -11.83M | 420.01M |
Total Current Assets | 30.85B | 22.26B | 22.61B | 21.89B | 26.45B | 26.74B | 24.38B | 23.96B | 22.83B | 20.3B | 19.12B |
Property-Plant & Equipment | 13.64B | 13.5B | 13.63B | 13.08B | 12.23B | 12.23B | 11.36B | 11.77B | 10.08B | 9.55B | 9.17B |
Goodwill & Intangibles | 3.22B | 3.01B | 2.89B | 2.84B | 2.47B | 2.43B | 2.5B | 2.34B | 1.69B | 766.44M | 759.38M |
Total Long-Term Assets | 25.16B | 24.46B | 23.39B | 22.5B | 21.42B | 19.54B | 19.29B | 17.81B | 16.01B | 14.38B | 13.74B |
Total Assets | 56.01B | 46.72B | 46B | 44.39B | 47.87B | 46.15B | 43.67B | 41.77B | 38.85B | 34.68B | 32.85B |
Account Payables | 2.7B | 2.98B | 2.29B | 2.61B | 3.23B | 2.84B | 2.36B | 2.01B | 1.79B | 1.32B | 1.48B |
Deferred Revenue | 640.45M | 662.53M | n/a | n/a | n/a | 325.24M | 232.75M | 788.16M | 255.17M | 427.63M | 329.04M |
Short-Term Debt | 263.45M | 328.72M | 247.46M | 392.2M | 202.56M | 450.22M | 55.37M | 153.48M | 384.58M | 38.35M | 95.02M |
Other Current Liabilities | 10.28B | 5.85B | 1.38B | 945.86M | 250.06M | 169.66M | 760.94K | -3.75B | -94K | -1.8B | -94.34M |
Total Current Liabilities | 14.42B | 10.18B | 10.11B | 9.63B | 10.44B | 10.18B | 9.03B | 8.96B | 8.46B | 7.21B | 6.92B |
Long-Term Debt | 274.36M | n/a | n/a | n/a | n/a | n/a | 19.9M | 28.95M | 11.79M | n/a | n/a |
Other Long-Term Liabilities | 540.54M | 563.48M | 481.68M | 407.81M | 350.58M | 56.96M | 372.32M | 270.92M | 242.6M | 250.2M | 204.73M |
Total Long-Term Liabilities | 2.17B | 1.97B | 1.03B | 888.67M | 988.7M | 738.86M | 1.14B | 1.17B | 964.48M | 687.3M | 624.45M |
Total Liabilities | 16.59B | 12.15B | 11.14B | 10.52B | 11.42B | 11.26B | 10.16B | 10.13B | 9.42B | 7.91B | 7.55B |
Total Debt | 652.37M | 641.38M | 495M | 507.33M | 388.87M | 706.9M | 415.26M | 582.54M | 682.56M | 93.87M | 154.53M |
Book Value | 39.42B | 34.56B | 34.86B | 33.87B | 36.45B | 34.88B | 33.51B | 31.64B | 29.43B | 26.77B | 25.31B |
Book Value Per Share | 3.45 | 3 | 3.05 | 2.91 | 3.08 | 2.94 | 2.82 | 2.65 | 2.47 | 2.24 | 2.12 |
Common Stock | 11.06B | 11.07B | 11.04B | 11.03B | 11.01B | 10.87B | 10.9B | 10.75B | 10.9B | 10.88B | 10.9B |
Retained Earnings | n/a | 24.48B | 24.51B | 23.34B | 25.03B | 21.77B | 22.86B | 20.84B | 19.2B | 17.24B | 15.7B |
Comprehensive Income | n/a | n/a | n/a | n/a | n/a | -1.41B | n/a | -1.73B | -1.96B | -2.09B | -2B |
Shareholders Equity | 37.62B | 33.19B | 33.25B | 32.26B | 34.83B | 33.1B | 31.82B | 29.77B | 28.05B | 25.94B | 24.5B |
Total Investments | 16.04B | 9.96B | 8.79B | 6.27B | 8.88B | 5.72B | 4.66B | 7.25B | 7.7B | 5.04B | 6.51B |
Add to Watchlist
Select watchlists to add or remove CSPCY